Severe headache in primary Sjögren's syndrome treated with intrathecal rituximab
Peer reviewed, Journal article
Published version

Åpne
Permanent lenke
https://hdl.handle.net/1956/22718Utgivelsesdato
2019-01-17Metadata
Vis full innførselSamlinger
Originalversjon
https://doi.org/10.1002/ccr3.1987Sammendrag
A severe and persistent migrainous headache in a patient with primary Sjøgren's syndrome unresponsive to treatment with immunosuppressive drugs, triptans, opioids, and NSAIDs, responded successfully to intrathecal B‐cell depletion with rituximab. We hypothesize that brain‐resident autoreactive B cells were involved in headache pathogenesis and were eliminated by this procedure.